Phase III Sytrinol Trial Completed

Phase III Sytrinol Trial Completed

CHICAGOSourceOne GlobalPartners announced it completed the final phase of a three-phase clinical trialon its proprietary cardiovascular compound, Sytrinol, a patented formulacombining citrus flavones and palm tocotrienols. The Phase III results areconsistent with those of the first two segments, which found the compound couldsignificantly improve total cholesterol, LDL cholesterol and triglycerides by upto 30 percent, 27 percent and 33 percent, respectively, compared to placebo in120 modera t e l y hypercholesterolemic men and women.

SourceOne also announced the launch of a double blind,placebo-controlled, randomized study to investigate the impact of combiningSytrinol and plant sterols, which work to block cholesterol absorption in thedigestive tract.